{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:18Z","timestamp":1787026998776,"version":"build-2736575974"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Germ-line EGFR mutations are rare, and their clinical significance, particularly regarding response to tyrosine kinase inhibitors (TKIs), remains poorly defined. The EGFR V831H (also known as R831H) mutation is an exceptionally rare variant with constitutive activity, and data on its therapeutic sensitivity are scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We present a detailed case report of a patient with advanced non-small cell lung cancer (NSCLC) harboring a germ-line EGFR V831H mutation. Diagnosis involved imaging, histopathology, and comprehensive genomic profiling of tumor tissue. Germ-line origin was confirmed via Sanger sequencing of normal patient tissue and a familial sample.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 68-year-old man was diagnosed with stage IIIB lung adenocarcinoma and concurrent latent tuberculosis infection (LTBI). Next-generation sequencing of a lymph node biopsy revealed co-occurring somatic KRAS G12V and an EGFR exon 21 V831H mutation, which was subsequently identified as a germ-line variant. The patient initiated antituberculosis therapy (rifampicin and isoniazid) followed by the third-generation EGFR-TKI almonertinib (110 mg\/day).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The disease demonstrated primary resistance to almonertinib, with radiological progression in thoracic lymph nodes observed within 20 days of treatment initiation. The patient died one month later with evidence of new brain metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights primary resistance to the third-generation EGFR-TKI almonertinib in a patient with NSCLC harboring a germ-line EGFR V831H mutation. The rapid progression suggests that this specific germ-line variant may confer inherent TKI resistance, potentially exacerbated by the presence of a concurrent KRAS G12V mutation and drug-drug interactions between almonertinib and antituberculosis medications. It underscores the clinical challenge of germ-line EGFR mutations and emphasizes the need for further research to establish effective therapeutic strategies for such rare genotypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1758636","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:32:50Z","timestamp":1771392770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Germ-line exon 21 EGFR V831H mutation in advanced NSCLC resistance to almonertinib: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Daxia","family":"Cai","sequence":"first","affiliation":[{"name":"Cancer Center, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University","place":["Lishui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Lou","sequence":"additional","affiliation":[{"name":"Cancer Center, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University","place":["Lishui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Lishui Municipal Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University","place":["Lishui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Wang","sequence":"additional","affiliation":[{"name":"Cancer Center, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University","place":["Lishui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1342086","article-title":"NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy","volume":"151342086","author":"Raskova Kafkova","year":"2024","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102895","article-title":"Lung cancer in never smokers: The role of different risk factors other than tobacco smoking","volume":"148102895","author":"Corrales","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2024.04.009","article-title":"A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review","volume":"25","author":"Sharma","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"B5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial Risk and Heritability of Cancer Among Twins in Nordic Countries","volume":"315","author":"Mucci","year":"2016","journal-title":"Jama."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ng1671","article-title":"Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR","volume":"37","author":"Bell","year":"2005","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.774156","article-title":"Identification of the unique clinical and genetic features of chinese lung cancer patients with EGFR germline mutations in a large-scale retrospective study","volume":"11774156","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3892\/ol.2023.13868","article-title":"Germline EGFR mutations in lung cancer (Review)","volume":"26","author":"Liu","year":"2023","journal-title":"Oncol letters"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01372","article-title":"Germline EGFR Mutations and Familial Lung Cancer","volume":"41","author":"Oxnard","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0938","article-title":"Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation","volume":"25","author":"Huo","year":"2020","journal-title":"Oncologist."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.12.006","article-title":"EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer","volume":"14","author":"Lu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jtbi.2018.12.035","article-title":"Hydrogen bond analysis of the EGFR-ErbB3 heterodimer related to non-small cell lung cancer and drug resistance","volume":"2019","author":"Ghosh","year":"2019","journal-title":"J Theor Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-25-0391","article-title":"Germline EGFR T790M in lung cancer: prevalence, clinical impact, and implications for hereditary risk","author":"Melikova","year":"2025","journal-title":"Cancer Prev Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.06.004","article-title":"Mutational characteristics and clinical outcomes for lung adenocarcinoma with EGFR germline mutations","volume":"19","author":"Pan","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13053-024-00286-4","article-title":"Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations","volume":"22","author":"Li","year":"2024","journal-title":"Hereditary Cancer Clin Practice"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2022.381","article-title":"Real-world study of osimertinib in korean patients with epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer","volume":"55","author":"Lee","year":"2023","journal-title":"Cancer Res Treat"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30480-0","article-title":"Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study","volume":"6","author":"Lin","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.cytogfr.2023.03.003","article-title":"Multiple post-translational modifications ensure EGFR functionality: Potential therapeutic targets to overcome its drug-resistance mutations","volume":"2023","author":"He","year":"2023","journal-title":"Cytokine Growth Factor Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1176868","DOI":"10.3389\/fonc.2023.1176868","article-title":"Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation","volume":"2023","author":"Sagan","year":"2023","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.rmcr.2018.03.009","article-title":"EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer","volume":"2018","author":"Sonoda","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12967-025-06096-z","article-title":"Comprehensive genomic profiling of Chinese lung cancer characterizes germline-somatic mutation interactions influencing cancer risk","volume":"23","author":"Zhou","year":"2025","journal-title":"J Trans Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.05.036","article-title":"Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation","volume":"2021","author":"Guo","year":"2021","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"108393","DOI":"10.1016\/j.bioorg.2025.108393","article-title":"A novel MMP-9 inhibitor exhibits selective inhibition in non-small-cell lung cancer harboring EGFR T790M mutation by blocking EGFR\/STAT3 signaling pathway","volume":"2025","author":"Li","year":"2025","journal-title":"Bioorganic Chem"},{"key":"B24","doi-asserted-by":"publisher","first-page":"107543","DOI":"10.1016\/j.lungcan.2024.107543","article-title":"Familial rare EGFR-mutant lung cancer syndrome: Review of literature and description of R776H family","volume":"2024","author":"Gabriel","year":"2024","journal-title":"Lung Cancer"},{"key":"B25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3892\/ol.2023.13868","article-title":"Germline EGFR mutations in lung cancer (Review)","volume":"26","author":"Liu","year":"2023","journal-title":"Oncol Letters"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0736","article-title":"Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing","volume":"15","author":"Kohsaka","year":"2019","journal-title":"Future Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.21037\/tlcr.2018.06.01","article-title":"Inherited lung cancer syndromes targeting never smokers","volume":"7","author":"Yamamoto","year":"2018","journal-title":"Trans Lung Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"774156","DOI":"10.3389\/fonc.2021.774156","article-title":"Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study","volume":"2021","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddab172","article-title":"Germline ERBB3 mutation in familial non-small-cell lung carcinoma: expanding ErbB's role in oncogenesis","volume":"30","author":"McInerney-Leo","year":"2021","journal-title":"Hum Mol Genet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"498","DOI":"10.21037\/tlcr.2018.06.01","article-title":"Inherited lung cancer syndromes targeting never smokers","volume":"7","author":"Yamamoto","year":"2018","journal-title":"Trans Lung Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.06.004","article-title":"Mutational characteristics and clinical outcomes for lung adenocarcinoma with EGFR germline mutations","volume":"19","author":"Pan","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12920-025-02113-8","article-title":"Inherited rare epidermal growth factor receptor mutation and somatic mutations in patients with non-small cell lung cancer: a case report","volume":"18","author":"Saridaki","year":"2025","journal-title":"BMC Med Genomics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.610923","article-title":"Concurrent genetic alterations and other biomarkers predict treatment efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer: A review","volume":"10610923","author":"Guo","year":"2020","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"107247","DOI":"10.1016\/j.lungcan.2023.107247","article-title":"Germline EGFR c.2527G > A (p.V843I) variant and familial lung cancer","volume":"2023","author":"Alsaddah","year":"2023","journal-title":"Lung Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"117178","DOI":"10.1016\/j.ejmech.2024.117178","article-title":"From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer","volume":"2025","author":"Ahmad","year":"2025","journal-title":"Eur J Medicinal Chem"},{"key":"B36","doi-asserted-by":"publisher","first-page":"869390","DOI":"10.3389\/fonc.2022.869390","article-title":"Comparison of T790M Acquisition After Treatment With First- and Second-Generation Tyrosine-Kinase Inhibitors: A Systematic Review and Network Meta-Analysis","volume":"2022","author":"Hsieh","year":"2022","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-1","article-title":"Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review","volume":"11","author":"Passiglia","year":"2022","journal-title":"Trans Lung Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"20220768","DOI":"10.1515\/biol-2022-0768","article-title":"Exploring the conformational dynamics and thermodynamics of EGFR S768I and G719X + S768I mutations in non-small cell lung cancer: An in silico approaches","volume":"18","author":"Wang","year":"2023","journal-title":"Open Life Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.08.007","article-title":"Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing","volume":"2020","author":"Christopoulos","year":"2020","journal-title":"Lung Cancer"},{"key":"B40","article-title":"PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer","volume":"38","author":"Goc","year":"2011","journal-title":"Int J Of Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e444","DOI":"10.1097\/MD.0000000000000444","article-title":"Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S326349","article-title":"Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor","author":"Xie","year":"2021","journal-title":"Cancer Manage Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-021-00710-8","article-title":"Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers","volume":"43","author":"Liu","year":"2022","journal-title":"Acta Pharmacologica Sinica"},{"key":"B44","doi-asserted-by":"publisher","first-page":"123231","DOI":"10.1016\/j.jchromb.2022.123231","article-title":"Simultaneous determination of almonertinib and its active metabolite HAS-719 in human plasma by LC-MS\/MS: Evaluation of pharmacokinetic interactions","volume":"2022","author":"Liu","year":"2022","journal-title":"J Chromatogr B Analyt Technol BioMed Life Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13534","article-title":"The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib","volume":"84","author":"Vishwanathan","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01071-z","article-title":"Effects of rifampicin on the pharmacokinetics of alflutinib, a selective third-generation EGFR kinase inhibitor, and its metabolite AST5902 in healthy volunteers","volume":"39","author":"Zhu","year":"2021","journal-title":"Investigational New Drugs"},{"key":"B47","doi-asserted-by":"publisher","first-page":"821807","DOI":"10.3389\/fonc.2022.821807","article-title":"Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples","volume":"2022","author":"Verougstraete","year":"2022","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16070","article-title":"Therapeutic drug monitoring of osimertinib in EGFR mutant non-small cell lung cancer by dried blood spot and plasma collection: A pilot study","volume":"90","author":"Narayanan","year":"2024","journal-title":"Br J Clin Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04432-4","article-title":"Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer","volume":"89","author":"Gandhi","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1016\/j.clinthera.2019.10.009","article-title":"Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis","volume":"41","author":"Garc\u00eda-Ferrer","year":"2019","journal-title":"Clin Ther"},{"key":"B51","doi-asserted-by":"crossref","first-page":"113393","DOI":"10.1016\/j.biopha.2022.113393","article-title":"Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer","volume":"2022","author":"Guchelaar","year":"2022","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14332","article-title":"The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour","volume":"87","author":"Westerdijk","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B53","first-page":"123245","article-title":"Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum","volume":"2022","author":"Ishikawa","year":"1199","journal-title":"J Chromatogr B Analyt Technol BioMed Life Sci"},{"key":"B54","doi-asserted-by":"publisher","first-page":"115697","DOI":"10.1016\/j.jpba.2023.115697","article-title":"A fully validated method for simultaneous determination of icotinib, osimertinib, gefitinib and O-desmethyl gefitinib in human plasma using UPLC-MS\/MS for therapeutic drug monitoring","volume":"2023","author":"Li","year":"2023","journal-title":"J Pharm Biomed Analysis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41467-017-00450-6","article-title":"Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer","volume":"8","author":"Jacobsen","year":"2017","journal-title":"Nat Commun"},{"key":"B56","doi-asserted-by":"publisher","first-page":"101026","DOI":"10.1016\/j.ctarc.2025.101026","article-title":"Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer","volume":"2025","author":"Levine","year":"2025","journal-title":"Treat Res Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01237-4","article-title":"Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"45","author":"Han","year":"2024","journal-title":"Acta Pharmacologica Sinica"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061604","article-title":"The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies","volume":"15","author":"Laface","year":"2023","journal-title":"Pharmaceutics"}],"updated-by":[{"DOI":"10.3389\/fonc.2026.1836262","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000}}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1758636\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T12:49:38Z","timestamp":1776084578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1758636\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":58,"alternative-id":["10.3389\/fonc.2026.1758636"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1758636","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1758636"}}